



IrsiCaixa

Institut de Recerca de la Sida

Hospital Germans Trias i Pujol
Badalona



New assays for assessing viral reservoirs




8th November 2022




M^aCarmen Puertas, PhD
Associate Researcher


- ✓ Total HIV eradication from the body is unlikely, instead a **functional cure** might be reached, which means control HIV in absence of antiretroviral treatment.
- ✓ Cases of natural or post-treatment control all have in common a small HIV reservoir size.

- ✓ Total HIV eradication from the body is unlikely, instead a **functional cure** might be reached, which means control HIV in absence of antiretroviral treatment.
- ✓ Cases of natural or post-treatment control all have in common a small HIV reservoir size.






❖ Analytical Treatment Interruption:




Participants' risks
and psychological aspects
(deal with expectations vs. dissapointment)

❖ Surrogate Marker of Effective Virological Response:





Recommendations for measuring HIV reservoir size in cure-directed clinical trials






Total Proviral DNA measured by droplet digital PCR (ddPCR)



- ✓ Very sensitive and precise, and convenient for measuring the size of the viral reservoir in naual infection (heterogeneous among people with HIV)



Total Proviral DNA measured by droplet digital PCR (ddPCR)






Bruner et al, Nat Med, 2016

- ✓ About 98% of HIV sequences are defective !!
But sequencing all the viral repertoire is unaffordable in the clinical setting



Intact Proviral DNA Assay (IPDA)





- ✓ Many samples (30%) fail because of variability in the viral sequence
- ✓ Designed for Subtype B HIV-1

Bruner et al, Nature, 2019




Intact Proviral DNA Assay (IPDA)




<https://jackwestin.com/resources>

- ✓ Most intact proviruses are non-inducible, sometimes because they are integrated in silent areas of the cell genome




TOTAL PROVIRAL DNA
measured by ddPCR

INTACT PROVIRUSES
measured by IPDA



- ✓ Poor results of previous shock-and-kill interventions...
Are we using the right tools to detect their effect?




FUNCTIONAL RESERVOIR

Production of
viral proteins =
viral antigens


**TOTAL
PROVIRAL DNA**


INTACT PROVIRUSES

**Replication-competent
Reservoir (qVOA)**






- ❖ Quantify the frequency of peripheral CD4⁺ T cells able to reactivate and produce viral proteins (p24).






- ✓ Elispot-based assay : detection of viral proteins at the **single-cell level**.
- ✓ VIP-SPOT shows good **sensitivity and reproducibility** at the lower ranges (down to 1 in 10^5 cells per well)
- ✓ **Scalable** in terms of sample needs (20×10^6 criopreserved PBMCs), procedure format (96-well plates) and working time (2 days).

*N=18 viremic samples




- VIP-SPOT correlates with other measures of viral burden in untreated HIV-1 infection


*N=35 ART suppressed



- VIP-SPOT measures the inducible HIV antigen-producing reservoir and correlates with other measures of viral persistence during suppressive ART



- The frequency of inducible p24-producing cells is 1000-fold lower than total HIV DNA and 100-fold lower than the intact proviral reservoir, thus indicating that viral reactivation is strongly restrained in long-lived reservoir cells.




❖ Shock&kill intervention at the time of ART initiation

nature medicine



Article

<https://doi.org/10.1038/s41591-022-02023-7>

Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trial




- ✓ Longitudinal changes in the frequency of HIV-Ag producing cells along the study period.




- ✓ Only half of the individuals (49%) had HIV-1 subtype B infection while the rest of the participants had a broad range of other HIV-1 subtypes and recombinant forms


- ✓ Only half of the individuals (49%) had HIV-1 subtype B infection while the rest of the participants had a broad range of other HIV-1 subtypes and recombinant forms






- ✓ Only half of the individuals (49%) had HIV-1 subtype B infection while the rest of the participants had a broad range of other HIV-1 subtypes and recombinant forms



❖ Evaluation of viral reactivation



❖ Evaluation of viral reactivation with non-clonal latently infected cell models



➤ Two novel LRAs identified

- ✓ **Total HIV DNA and Intact proviral DNA (IPDA)** are convenient assays to measure the size of the viral reservoir in natural HIV infection, but most viral genomes are defective or non-inducible.
- ✓ **VIP-SPOT is a novel assay** to precisely quantify the frequency of infected cells that retain the ability to reverse HIV-1 from latency and to produce viral antigens.
- ✓ This assay might be specially useful for evaluation of **therapeutic strategies based on immune clearance**, since the **productive reservoir** is the specific population that is going to be targeted by these interventions.
- ✓ The VIP-SPOT assay is robust, **cross-clade sensitive**, and suitable for longitudinal and multicenter retrospective/prospective clinical trials.
- ✓ Adapted versions of the VIP-SPOT are useful for **evaluating the efficacy of latency-reversing agents** in cell lines and primary cells.



IrsiCaixa
Institut de Recerca de la Sida



Generalitat de Catalunya
Departament de Salut



Obra Social "la Caixa"

ciberinfec isciii

GRIFOLS GILEAD

Maria C. Puertas
Ángel Bayón
Mari Carmen García
Sara Morón-López
María Salgado
Víctor Urrea
Javier Martínez-Picado



Ruth Peña
Esther Jiménez-Moyano
Julia G. Prado




Ifeany Ezeonwumelu
Ester Ballana



eCLEAR study group

HOT TOPICS
IN HIV

VIP-SPOT: an Innovative Assay To Quantify the Productive HIV-1 Reservoir in the Monitoring of Cure Strategies



**Dept of Infectious Diseases,
Aarhus University Hospital**

- **Jesper Damsgaard Gunst**
- **Miriam Rosas-Umbert**
- **Marie Høst Pahu**
- Martin Tolstrup
- Silke Dahlbom Nielsen
- Lars Østergaard
- Mariane Schleimann
- Rikke Olesen
- Paul W Denton
- I-Na Lu

- Jesper Falkesgaard Højen
- The Clinical Research Unit
- Janne Martinsen
- Lene Svinth Jøhnke, and many more...

**Lab for Molecular Immunology,
The Rockefeller University**

- **Michel Nussenzweig**
- **Marina Caskey**
- Yehuda Cohen
- Victor Ramos

**Imperial College/St Mary's
hospital**

- **Sarah Fidler**
- Maryam Khan
- Amin Alamshah

King's College London/GSST

- Julie Fox

.. and participants!

The Jones Lab, Weill-Cornell U

- Brad Jones
- Dennis Copertino
- Winiffrer Conce Alberto
- Adam Rackley Ward

The Brumme lab, Simon Fraser U

- Zabrina Brumme
- Natalie Kinloch

Celgene

- Anna Nielsson



Jesper D. Gunst
Ole S. Søgaard

**AARHUS
UNIVERSITY**